Yu D - Search Results

1

The importance of developing therapies targeting the biological spectrum of metastatic disease.

Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA; Board Members of the Metastasis Research Society. Zijlstra A, et al. Among authors: yu d. Clin Exp Metastasis. 2019 Aug;36(4):305-309. doi: 10.1007/s10585-019-09972-3. Epub 2019 May 17. Clin Exp Metastasis. 2019. PMID: 31102066 Free PMC article.

2

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.

Yu D, Hung MC. Yu D, et al. Oncogene. 2000 Dec 11;19(53):6115-21. doi: 10.1038/sj.onc.1203972. Oncogene. 2000. PMID: 11156524 Review.

3

Growth factor signaling in metastasis: current understanding and future opportunities.

Lowery FJ, Yu D. Lowery FJ, et al. Among authors: yu d. Cancer Metastasis Rev. 2012 Dec;31(3-4):479-91. doi: 10.1007/s10555-012-9380-x. Cancer Metastasis Rev. 2012. PMID: 22706845 Review.

4

Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products.

Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC. Yu D, et al. Oncogene. 1992 Nov;7(11):2263-70. Oncogene. 1992. PMID: 1359495

5

c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. Yu D, et al. Cancer Res. 1994 Jun 15;54(12):3260-6. Cancer Res. 1994. PMID: 7911396

6

E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.

Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. Ueno NT, et al. Among authors: yu d. Clin Cancer Res. 2000 Jan;6(1):250-9. Clin Cancer Res. 2000. PMID: 10656456

7

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.

Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Klos KS, et al. Among authors: yu d. Cancer. 2003 Oct 1;98(7):1377-85. doi: 10.1002/cncr.11656. Cancer. 2003. PMID: 14508823 Free article.

8

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Li YM, et al. Among authors: yu d. Cancer Cell. 2004 Nov;6(5):459-69. doi: 10.1016/j.ccr.2004.09.027. Cancer Cell. 2004. PMID: 15542430 Free article.

9

A knotty turnabout?: Akt1 as a metastasis suppressor.

Wyszomierski SL, Yu D. Wyszomierski SL, et al. Among authors: yu d. Cancer Cell. 2005 Dec;8(6):437-9. doi: 10.1016/j.ccr.2005.11.006. Cancer Cell. 2005. PMID: 16338656 Free article. Review.

10

Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.

Tan M, Li P, Sun M, Yin G, Yu D. Tan M, et al. Among authors: yu d. Oncogene. 2006 Jun 1;25(23):3286-95. doi: 10.1038/sj.onc.1209361. Epub 2006 Jan 23. Oncogene. 2006. PMID: 16407820

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,938 results

Search Page

Filters